Overview
Cardiac resynchronization therapy.
Implantable defibrillator, including inappropriate shocks.
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
Hypertrophic cardiomyopathy.
Long QT syndrome
Sudden cardiac arrest and resuscitation.
Ventricular tachycardia
Current Appointments & Affiliations
Professor of Medicine
·
2010 - Present
Medicine, Cardiology,
Medicine
Recent Publications
Rationale and design of the comparative effectiveness of ICD vs non-ICD therapy in contemporary heart failure patients at a low risk for arrhythmic death (CONTEMP-ICD) trial.
Journal Article Am Heart J · January 2026 BACKGROUND: Current recommendations for a prophylactic (primary prevention) implantable cardioverter defibrillator (ICD) in patients with both ischemic and nonischemic heart failure with reduced ejection fraction (HFrEF) originate from clinical trials cond ... Full text Link to item CiteReassessing the need for primary prevention implantable cardioverter-defibrillators in contemporary patients with heart failure.
Journal Article J Card Fail · August 2025 The main function of the implantable cardioverter-defibrillator (ICD) is to protect against sudden cardiac death (SCD) due to ventricular tachyarrhythmia (VTA). Current guidelines provide a recommendation to implant a prophylactic ICD for the primary preve ... Full text Link to item CiteEditorial commentary: Is it the atrial arrhythmia or the atrial myopathy? Yes! (It's both).
Journal Article Trends Cardiovasc Med · July 2025 Full text Link to item CiteRecent Grants
PKP2 Dose Escalation Trial of RP-A601
Clinical TrialPrincipal Investigator · Awarded by Rocket Pharmaceuticals, Ltd · 2024 - 2029The Natural History of Arrhythmogenic Cardiomyopathy with Pathogenic PKP2 Variants (PKP2-ACM): An observational cohort study
Clinical TrialPrincipal Investigator · Awarded by Rocket Pharmaceuticals, Ltd · 2025 - 2029A Phase 2 Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study To Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia
Clinical TrialPrincipal Investigator · Awarded by Cardurion Pharmaceuticals, Inc. · 2025 - 2027View All Grants
Education, Training & Certifications
Thomas Jefferson University ·
1984
M.D.